Current and former pro-athletes are joining noted Alzheimer’s specialist, Dr. Marc Agronin, for “Huddle Up For New Alzheimer’s Treatments,” a free event at Miami Jewish Health Systems, this Wednesday, April 20 from 10:30 am to 2 pm.
They’re raising awareness of Alzheimer’s disease, affecting 5 million Americans. No new treatments for Alzheimer’s disease have been approved by the FDA in 12 years. But at Miami Jewish Health, doctors are studying RVT-101, an investigational drug from Axovant, that has the potential to be the next meaningful advance in the treatment of Alzheimer’s disease.
The athletes attending Wednesday’s event include: current WQAM sportscaster and former Miami Dolphin Joe Rose; former Miami Hurricane and Denver Bronco K.C. Jones; current Pittsburgh Steeler and native Miamian Antonio Brown; and former Cincinnati Red and Miami native David Espinosa.
On Wednesday, those who sign-up can learn more about Alzheimer’s disease, its current and future treatments, meet the pro-athletes who are passionate about raising awareness and take part in free memory screenings. This is all vital in enrolling more people in clinical trials, which can help Alzheimer’s and dementia patients as soon as possible.
“Our Alzheimer’s educational session and memory screening for former players and their family members was very well-attended, and I am excited to partner with our local market ambassadors on a series of events for the general public that will bring the campaign to a wider audience,” said Solomon Wilcots.
“The message we want to share is if you or a loved one is experiencing problems related to memory loss or have a diagnosis of Alzheimer’s disease or dementia, join us at a Huddle Up event,” Wilcots added.
Originally from Los Angeles, Wilcots is a broadcaster with CBS Sports, NFL Network and SiriusXM. He spent six seasons in the NFL as a defensive back with the Bengals, Pittsburgh Steelers and Minnesota Vikings. As a member of the Cincinnati team, he played in Super Bowl XXIII.
“Huddle Up For New Alzheimer’s Treatments”
Wednesday April 20th
10:30am to 2pm
Ruby Auditorium
Miami Jewish Health Systems
5200 NE 2nd Ave.
Miami, FL 33137
RSVP is necessary at (305) 514-8710 or by visiting www.huddleupmiami.eventbrite.com.
Sponsored by Axovant Sciences Ltd., MINDSET is a double-blind, placebo-controlled study evaluating an investigational new drug candidate for mild-to-moderate Alzheimer’s disease known as RVT-101. RVT-101 is being studied as an add-on therapy to donepezil, the most widely used Alzheimer’s disease treatment today.
MINDSET’s objective is to confirm the results of a prior 684-patient study in which the combination of RVT-101 and donepezil was observed to provide statistically significant evidence of benefit to patients as compared to donepezil alone. RVT-101 has not been approved for any indication in any market. The MINDSET study could be the final step before RVT-101 is considered for approval by the FDA and regulatory bodies in other countries.
For more information on MINDSET, visit www.alzheimersglobalstudy.com.
It’s actually Axovant not Axovent.